OIL STATES INTERNATIONAL, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OIL STATES INTERNATIONAL, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.09B | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $670.63M | Feb 19, 2019 |
| FY2018 | Dec 31, 2016 | $694.44M | Feb 19, 2019 |
| FY2017 | Dec 31, 2015 | $1.10B | Feb 20, 2018 |
| FY2016 | Dec 31, 2014 | $1.82B | Feb 17, 2017 |
| FY2015 | Dec 31, 2013 | $1.63B | Feb 22, 2016 |
| FY2014 | Dec 31, 2012 | $1.52B | Feb 23, 2015 |
| FY2013 | Dec 31, 2011 | $2.10B | Feb 25, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $668.99M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $692.59M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $782.28M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $737.71M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $573.16M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $137.38M | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $134.76M | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | $146.25M | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | $219.69M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $238.36M | Feb 22, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $183.71M | Feb 20, 2018 |
| FY2017 | Sep 30, 2017 | $164.05M | Feb 20, 2018 |
| FY2017 | Jun 30, 2017 | $171.40M | Feb 20, 2018 |
| FY2017 | Mar 31, 2017 | $151.47M | Feb 20, 2018 |
| FY2017 | Dec 31, 2016 | $169.93M | Feb 20, 2018 |
| FY2017 | Sep 30, 2016 | $179.01M | Feb 20, 2018 |
| FY2017 | Jun 30, 2016 | $175.85M | Feb 20, 2018 |
| FY2017 | Mar 31, 2016 | $169.66M | Feb 20, 2018 |
| FY2016 | Dec 31, 2015 | $234.47M | Feb 17, 2017 |
| FY2016 | Sep 30, 2015 | $258.89M | Feb 17, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | ($1.16M) | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | ($9.89M) | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | ($6.30M) | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | ($4.16M) | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $16.51M | Feb 22, 2021 |
| FY2020 | Sep 30, 2019 | $31.43M | Feb 22, 2021 |
| FY2020 | Jun 30, 2019 | $24.87M | Feb 22, 2021 |
| FY2020 | Mar 31, 2019 | $19.45M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $25.93M | Feb 21, 2020 |
| FY2019 | Sep 30, 2018 | $28.57M | Feb 21, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($109.38M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($11.26M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $12.89M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | ($9.54M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | ($63.99M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($468.38M) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | ($231.81M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($19.11M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | ($84.85M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | ($46.39M) | Feb 19, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($97.97M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.69M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $23.16M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.91M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | ($64.79M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($534.34M) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | ($228.18M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($5.88M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | ($73.87M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | ($69.28M) | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.10M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.20M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.50M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.50M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $4.40M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $6.10M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $7.00M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $6.60M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $5.30M | Feb 21, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.43M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $95.01M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $94.19M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $96.04M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $83.69M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $94.10M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $122.93M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $138.07M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $114.82M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $124.03M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $105.12M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $45.89M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $56.58M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $32.86M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $7.19M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $132.76M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $137.43M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $103.17M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $95.38M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $149.26M | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $20.27M | Feb 17, 2023 |
| FY2022 | Dec 31, 2021 | $17.52M | Feb 17, 2023 |
| FY2022 | Dec 31, 2020 | $12.75M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $56.12M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $88.02M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $35.17M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $29.69M | Feb 19, 2019 |
| FY2017 | Dec 31, 2015 | $114.74M | Feb 20, 2018 |
| FY2016 | Dec 31, 2014 | $199.26M | Feb 17, 2017 |
| FY2015 | Dec 31, 2013 | $164.90M | Feb 22, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $883.43M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.05B | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.06B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $1.09B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.15B | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.73B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $2.00B | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $1.30B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $1.38B | Feb 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $310.24M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $324.45M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $336.94M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $374.83M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $389.92M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $394.63M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $503.90M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $564.05M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $168.80M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $179.59M | Feb 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $573.19M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $680.65M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $709.55M | Mar 26, 2026 |
| FY2025 | Dec 31, 2022 | $689.56M | Mar 26, 2026 |
| FY2024 | Dec 31, 2021 | $695.83M | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $757.63M | Feb 21, 2024 |
| FY2022 | Dec 31, 2019 | $1.22B | Feb 17, 2023 |
| FY2021 | Dec 31, 2018 | $1.44B | Feb 22, 2022 |
| FY2018 | Dec 31, 2017 | $1.13B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $1.20B | Feb 20, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.52M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $69.71M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $79.87M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $79.28M | Feb 21, 2025 |
| FY2022 | Dec 31, 2021 | $76.41M | Feb 17, 2023 |
| FY2021 | Dec 1, 2021 | $76.00M | Feb 22, 2022 |
| FY2022 | Dec 31, 2020 | $76.49M | Feb 17, 2023 |
| FY2021 | Dec 1, 2020 | $76.00M | Feb 22, 2022 |
| FY2020 | Mar 31, 2020 | $406.10M | Feb 22, 2021 |
| FY2021 | Dec 31, 2019 | $482.31M | Feb 22, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $164.28M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $273.66M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $284.92M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $272.03M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $281.57M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $329.33M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $797.71M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.03B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $1.05B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $1.13B | Feb 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.91M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $65.36M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $47.11M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $42.02M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $52.85M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $72.01M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $8.49M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $19.32M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $53.46M | Feb 19, 2019 |
| FY2018 | Dec 31, 2016 | $68.80M | Feb 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.67M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $124.65M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $135.50M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $135.07M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $160.49M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $165.76M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $248.17M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $331.74M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $5.28M | Feb 19, 2019 |
| FY2016 | Dec 31, 2016 | $45.93M | Feb 17, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | (7) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | (1) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 19, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | (7) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | (1) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 19, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 59.66M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 61.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | 63.33M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | 63.90M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 61.38M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 61.01M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | 60.50M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 59.97M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | 51.09M | Feb 21, 2020 |
| FY2017 | Dec 31, 2016 | 51.37M | Feb 20, 2018 |